Caribou Biosciences, Inc. (CRBU)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CRBU price, last 12 months
Key stats
- Previous close
- $1.25
- Open
- $1.25
- Day range
- $1.22 – $1.27
- 52-week range
- $1.22 – $3.54
- Volume
- 901.3K
- Avg volume (20 days)
- 1.2M
- Market cap
- $132.9M
Performance
Technicals and fundamentals
About Caribou Biosciences, Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $132.9M